Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Orna Therapeutics
Biotech
How Boston biotechs cope with shallower pool of seed funding
With the average seed round dropping 40% in the first half of the year, CEOs and investors told Fierce where they think the industry is heading.
Will Maddox
Oct 16, 2026 7:00am
Lilly buys Orna in $2.4B deal to enter in vivo CAR-T arena
Feb 9, 2026 8:41am
FDA rocked by leadership shake-ups—Chutes & Ladders
Apr 4, 2025 8:30am
Vertex and Orna team up to develop new blood disorder treatments
Jan 7, 2025 7:00am
BIO, Seaport, Orna and more—Chutes & Ladders
Apr 12, 2024 8:30am
ReNAgade lays off 10% of staff 6 months after $300M series A
Dec 5, 2023 10:15am
